Abstract.
Rubinstein-Taybi syndrome (RTS) is a rare human genetic disorder characterized by mental retardation and physical abnormalities. Many RTS patients have a genetic mutation which has been mapped to chromosome 16p13.3, a genomic region encoding cyclic AMP (cAMP) response element binding protein (CREB) binding protein (CBP). CBP is a transcriptional co-activator that binds to CREB when the latter is phosphorylated and promotes gene transcription. CREB-dependent gene transcription has been shown to underlie long-term memory formation. In this review we will focus on recent findings regarding the biology of CBP and its role in memory formation and cognitive dysfunction in RTS. We will also review the role of CBP in other neurological disorders, including Alzheimer’s disease, Huntington’s disease and amyotrophic lateral sclerosis. Finally, we will discuss novel therapeutic approaches targeted to CBP/CREB function for treating the cognitive dysfunction of RTS and other neurological disorders.
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Additional information
Received 18 November 2005; received after revision 22 February 2006; accepted 18 April 2006
Rights and permissions
About this article
Cite this article
Hallam, T.M., Bourtchouladze, R. Rubinstein-Taybi syndrome: molecular findings and therapeutic approaches to improve cognitive dysfunction. Cell. Mol. Life Sci. 63, 1725 (2006). https://doi.org/10.1007/s00018-005-5555-8
Published:
DOI: https://doi.org/10.1007/s00018-005-5555-8